News & Media

Recent updates from Arcutis.

May 7, 2025

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

May 6, 2025

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

May 2, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 17, 2025

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

April 10, 2025

Arcutis Announces Chief Financial Officer Transition

April 4, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 2, 2025

Arcutis and Padagis Agree to Stay Patent Lawsuit

March 27, 2025

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

March 7, 2025

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

March 5, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 28, 2025

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

February 26, 2025

U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download